Pro-Dex, Inc. (NASDAQ:PDEX) Director Sells $41,800.00 in Stock

Pro-Dex, Inc. (NASDAQ:PDEX) Director Raymond E. Cabillot sold 836 shares of the stock in a transaction on Monday, March 31st. The stock was sold at an average price of $50.00, for a total value of $41,800.00. Following the completion of the transaction, the director now directly owns 278,109 shares in the company, valued at $13,905,450. This trade represents a 0.30 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

Pro-Dex Stock Performance

Shares of PDEX stock opened at $55.19 on Thursday. The company has a current ratio of 2.58, a quick ratio of 1.44 and a debt-to-equity ratio of 0.33. The company has a market cap of $179.97 million, a PE ratio of 27.46 and a beta of 0.40. The company’s fifty day simple moving average is $40.72 and its 200-day simple moving average is $40.53. Pro-Dex, Inc. has a 52 week low of $16.84 and a 52 week high of $59.60.

Pro-Dex (NASDAQ:PDEX) last released its quarterly earnings data on Thursday, January 30th. The medical instruments supplier reported $0.61 EPS for the quarter, beating the consensus estimate of $0.38 by $0.23. Pro-Dex had a return on equity of 21.68% and a net margin of 11.06%. As a group, equities research analysts anticipate that Pro-Dex, Inc. will post 2 EPS for the current year.

Analysts Set New Price Targets

Separately, StockNews.com lowered Pro-Dex from a “buy” rating to a “hold” rating in a research note on Wednesday, March 12th.

Institutional Investors Weigh In On Pro-Dex

Several hedge funds have recently modified their holdings of the stock. Ritholtz Wealth Management acquired a new stake in Pro-Dex in the fourth quarter valued at approximately $572,000. FMR LLC boosted its stake in shares of Pro-Dex by 34.9% in the third quarter. FMR LLC now owns 3,973 shares of the medical instruments supplier’s stock valued at $119,000 after purchasing an additional 1,028 shares during the period. Geode Capital Management LLC grew its holdings in Pro-Dex by 9.1% during the 3rd quarter. Geode Capital Management LLC now owns 27,435 shares of the medical instruments supplier’s stock valued at $819,000 after purchasing an additional 2,296 shares in the last quarter. Bank of New York Mellon Corp purchased a new stake in Pro-Dex during the 4th quarter worth $202,000. Finally, JPMorgan Chase & Co. lifted its holdings in Pro-Dex by 2.2% in the 3rd quarter. JPMorgan Chase & Co. now owns 24,790 shares of the medical instruments supplier’s stock worth $740,000 after buying an additional 529 shares in the last quarter. 15.28% of the stock is currently owned by hedge funds and other institutional investors.

About Pro-Dex

Pro-Dex, Inc designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets.